{"id":"NCT01663402","sponsor":"Sanofi","briefTitle":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2018-01-23","completion":"2018-01-23","firstPosted":"2012-08-13","resultsPosted":"2019-03-18","lastUpdate":"2019-03-18"},"enrollment":18924,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"LMT","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, CHD deaths, CV deaths, all cause mortality).\n* To evaluate the safety and tolerability of alirocumab.\n* To evaluate the effect of alirocumab on lipid parameters.","primaryOutcome":{"measure":"Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study","timeFrame":"From randomization up to 64 months","effectByArm":[{"arm":"Placebo","deltaMin":11.1,"sd":null},{"arm":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","deltaMin":9.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":1388,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Estonia","Finland","France","Georgia","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","North Macedonia","Norway","Peru","Philippines","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sri Lanka","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40847481","40193536","39687787","39239905","39232634","37954898","37702079","37632469","37328736","36879424","35770629","35708715","35644332","35378068","35296402","34325831","33755145","33722880","33438437","33078867","33051646","32381160","32223446","31948641","31707826","31707788","31475572","31466614","31272931","31117810","30898609","30403574","25440796"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2350,"n":9443},"commonTop":["Hypertension","Nasopharyngitis","Myalgia","Blood Creatine Phosphokinase Increased","Non-Cardiac Chest Pain"]}}